<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T04:43:09Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5193002" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:5193002</identifier>
        <datestamp>2016-12-29</datestamp>
        <setSpec>cptpsp</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">CPT Pharmacometrics Syst Pharmacol</journal-id>
              <journal-id journal-id-type="iso-abbrev">CPT Pharmacometrics Syst Pharmacol</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2163-8306</journal-id>
              <journal-id journal-id-type="publisher-id">PSP4</journal-id>
              <journal-title-group>
                <journal-title>CPT: Pharmacometrics &amp; Systems Pharmacology</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2163-8306</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC5193002</article-id>
              <article-id pub-id-type="pmcid">PMC5193002</article-id>
              <article-id pub-id-type="pmc-uid">5193002</article-id>
              <article-id pub-id-type="pmid">27869362</article-id>
              <article-id pub-id-type="doi">10.1002/psp4.12146</article-id>
              <article-id pub-id-type="publisher-id">PSP412146</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Articles</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Fractal Geometry‐Based Decrease in Trimethoprim‐Sulfamethoxazole Concentrations in Overweight and Obese People</article-title>
                <alt-title alt-title-type="right-running-head">Obesity Reduces Cotrimoxazole Concentrations</alt-title>
                <alt-title alt-title-type="left-running-head">Hall <italic>et al</italic>.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="psp412146-cr-0001" contrib-type="author">
                  <name>
                    <surname>Hall</surname>
                    <given-names>RG</given-names>
                    <suffix>2nd</suffix>
                  </name>
                  <xref ref-type="aff" rid="psp412146-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="psp412146-cr-0002" contrib-type="author">
                  <name>
                    <surname>Pasipanodya</surname>
                    <given-names>JG</given-names>
                  </name>
                  <xref ref-type="aff" rid="psp412146-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="psp412146-cr-0003" contrib-type="author">
                  <name>
                    <surname>Meek</surname>
                    <given-names>C</given-names>
                  </name>
                  <xref ref-type="aff" rid="psp412146-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="psp412146-cr-0004" contrib-type="author">
                  <name>
                    <surname>Leff</surname>
                    <given-names>RD</given-names>
                  </name>
                  <xref ref-type="aff" rid="psp412146-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="psp412146-cr-0005" contrib-type="author">
                  <name>
                    <surname>Swancutt</surname>
                    <given-names>M</given-names>
                  </name>
                  <xref ref-type="aff" rid="psp412146-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="psp412146-cr-0006" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Gumbo</surname>
                    <given-names>T</given-names>
                  </name>
                  <address>
                    <email>tawanda.gumbo@baylorhealth.edu</email>
                  </address>
                  <xref ref-type="aff" rid="psp412146-aff-0002">
                    <sup>2</sup>
                  </xref>
                  <xref ref-type="aff" rid="psp412146-aff-0004">
                    <sup>4</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="psp412146-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Department of Pharmacy Practice</named-content>
                <institution>Texas Tech University Health Sciences Center, School of Pharmacy</institution>
                <named-content content-type="city">Austin</named-content>
                <named-content content-type="country-part">Texas</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="psp412146-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <institution>Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center</institution>
                <named-content content-type="city">Dallas</named-content>
                <named-content content-type="country-part">Texas</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="psp412146-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <institution>UT Southwestern Medical Center</institution>
                <named-content content-type="city">Dallas</named-content>
                <named-content content-type="country-part">Texas</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="psp412146-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <institution>University of Cape Town, Observatory</institution>
                <named-content content-type="city">Cape Town</named-content>
                <country country="ZA">South Africa</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>Correspondence: T Gumbo (<email>tawanda.gumbo@bswhealth.org</email>)</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>21</day>
                <month>11</month>
                <year>2016</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>12</month>
                <year>2016</year>
              </pub-date>
              <volume>5</volume>
              <issue>12</issue>
              <issue-id pub-id-type="doi">10.1002/psp4.v5.12</issue-id>
              <fpage>674</fpage>
              <lpage>681</lpage>
              <history>
                <date date-type="received">
                  <day>29</day>
                  <month>6</month>
                  <year>2016</year>
                </date>
                <date date-type="accepted">
                  <day>04</day>
                  <month>10</month>
                  <year>2016</year>
                </date>
              </history>
              <permissions>
                <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 ASCPT <copyright-statement>-->
                <copyright-statement content-type="article-copyright">© 2016 The Authors CPT: Pharmacometrics &amp; Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics</copyright-statement>
                <license license-type="creativeCommonsBy-nc-nd">
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution‐NonCommercial‐NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:PSP4-5-674.pdf"/>
              <abstract>
                <p>Trimethoprim‐sulfamethoxazole (TMP‐SMX) is one of the most widely drugs on earth. The World Health Organization recommends it as an essential basic drug for all healthcare systems. Dosing is inconsistently based on weight, assuming linear relationships. Given that obesity is now a global “pandemic” it is vital that we evaluate the effect of obesity on trimethoprim‐sulfamethoxazole concentrations. We conducted a prospective clinical experiment based on optimized design strategies and artificial intelligence algorithms and found that weight and body mass index (BMI) had a profound effect on drug clearance and volume of distribution, and followed nonlinear fractal geometry‐based relationships. The findings were confirmed by demonstrating decreased TMP‐SMX peak and area under the concentration‐time curves in overweight patients based on standard regression statistics. The nonlinear relationships can now be used to identify new TMP‐SMX doses in overweight and obese patients for each of the infections caused by the &gt;60 pathogens for which the drug is indicated.</p>
              </abstract>
              <funding-group>
                <award-group>
                  <funding-source>North and Central Texas Clinical and Translational Science Initiative
</funding-source>
                  <award-id>KL2RR024983
</award-id>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>National Center for Research Resources/National Institutes of Health
</funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>National Institutes of Health Clinical and Translational Science Awards
</funding-source>
                  <award-id>UL1RR024982
</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="3"/>
                <table-count count="4"/>
                <page-count count="8"/>
                <word-count count="5638"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>component-id</meta-name>
                  <meta-value>psp412146</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>December 2016</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.0 mode:remove_FC converted:28.12.2016</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <p>
              <boxed-text position="anchor" content-type="box" orientation="portrait">
                <caption>
                  <title>Study Highlights</title>
                </caption>
                <sec id="psp412146-sec-1012">
                  <p>
                    <bold>WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?</bold>
                  </p>
                  <p>☑ There are no data describing the PKs of TMP‐SMX in obese people.</p>
                  <p>
                    <bold>WHAT QUESTION DOES THIS STUDY ADDRESS?</bold>
                  </p>
                  <p>☑ The impact of body size on the TMP‐SMX concentrations and PK parameters.</p>
                  <p>
                    <bold>WHAT THIS STUDY ADDS TO OUR KNOWLEDGE</bold>
                  </p>
                  <p>☑ This study provides evidence that weight has a profound effect on TMP‐SMX clearance and volume of distribution, based on nonlinear fractal geometry‐based relationships. Second, it demonstrates the use of smaller clinical study populations based on optimal design and AI algorithms to identify complex clinical predictors.</p>
                  <p>
                    <bold>HOW MIGHT THIS CHANGE DRUG DISCOVERY, DEVELOPMENT, AND/OR THERAPEUTICS?</bold>
                  </p>
                  <p>☑ The use of AI requires much smaller patient sample sizes to identify important PK parameters for drug development and therapeutic studies than currently used in the field. Second, new TMP‐SMX doses may need to be increased for treatment of many infections in overweight and obese patients.</p>
                </sec>
              </boxed-text>
            </p>
            <p>Trimethoprim/sulfamethoxazole (TMP‐SMX) is commonly used worldwide to treat infections caused by up to 60 different bacterial, protozoal, and fungal species. Consequently, it is perhaps the most widely prescribed antibiotic in the world. As an example, it is recommended by the World Health Organization as one of the essential basic drugs for any healthcare system.<xref rid="psp412146-bib-0001" ref-type="ref">1</xref> The current dose recommendations for TMP‐SMX were established based on studies in children and then extrapolated to the adult population.<xref rid="psp412146-bib-0002" ref-type="ref">2</xref>, <xref rid="psp412146-bib-0003" ref-type="ref">3</xref> Pharmacokinetic (PK) studies using noncompartmental techniques in immunocompromised and critically ill patients have largely supported the same dosing regimen.<xref rid="psp412146-bib-0004" ref-type="ref">4</xref> The recommended dose has been capped at 100 mg/kg for sulfamethoxazole and 20 mg/kg for trimethoprim, based on a patient's total body weight (TBW). The underlying assumptions were that of a linear relationship among ideal body weight (IBW), TBW, and PK parameters, such as drug elimination and volume of distribution.<xref rid="psp412146-bib-0005" ref-type="ref">5</xref>, <xref rid="psp412146-bib-0006" ref-type="ref">6</xref> These assumptions were never formally tested for either drug in the combination and have been in use for more than 5 decades. The matter is now pressing because the population of the planet is now predominantly overweight and obese.<xref rid="psp412146-bib-0007" ref-type="ref">7</xref>, <xref rid="psp412146-bib-0008" ref-type="ref">8</xref> As an example, two of every three patients are either overweight or obese in the United States. In Polynesian countries, such as Tonga and Samoa, 90% of adults are obese, whereas in Middle Eastern countries, such as Egypt, 70% of women are obese.<xref rid="psp412146-bib-0009" ref-type="ref">9</xref> TMP‐SMX is already being extensively used in these populations. Here, we performed a prospective clinical experiment to identify the effect of obesity on TMP‐SMX.</p>
            <p>To date, we have examined up to eight antibiotics in carefully planned clinical experiments. In each single case, obesity was associated with changes in clearance and volume, which means that heavier patients achieved lower drug concentrations than leaner ones even when the same dose in milligram/kilogram was administered.<xref rid="psp412146-bib-0010" ref-type="ref">10</xref> The second emerging theme has been the relationship between such factors as clearance and volume to the fractal geometry of patients, in contradistinction to the idea of linear relationships between weight and xenobiotic metabolism or volume of distribution.<xref rid="psp412146-bib-0011" ref-type="ref">11</xref>, <xref rid="psp412146-bib-0012" ref-type="ref">12</xref>, <xref rid="psp412146-bib-0013" ref-type="ref">13</xref>, <xref rid="psp412146-bib-0014" ref-type="ref">14</xref>, <xref rid="psp412146-bib-0015" ref-type="ref">15</xref> In a bid to eliminate bias (i.e., one to find a relationship of weight to xenobiotic metabolism and volume of distribution), we have switched our analyses to agnostic machine learning or artificial intelligence (AI) algorithms. With this approach, all clinical parameters, including clinical chemistry results, demographics, physical examination findings and characteristics, comorbidities, weight measures (including IBW and TBW), height, body mass index (BMI), and body surface area (BSA), are examined as potential predictors of measures of drug elimination and volume in one model. We let the unbiased algorithms select and rank those significant factors that truly drive these PK parameters in order of importance, without the modeler tipping the scale in favor of their favorite covariate. We have previously used multiple adaptive regression splines (MARS) and Random Forests, including their forebear, classification and regression trees, for identifying and ranking covariates in PK and pharmacodynamic (PD) modelling exercises, and each time these approaches have outperformed the previously recommended industry standards based on parametric approaches and frequentist statistics.<xref rid="psp412146-bib-0016" ref-type="ref">16</xref>, <xref rid="psp412146-bib-0017" ref-type="ref">17</xref>, <xref rid="psp412146-bib-0018" ref-type="ref">18</xref>, <xref rid="psp412146-bib-0019" ref-type="ref">19</xref>, <xref rid="psp412146-bib-0020" ref-type="ref">20</xref>, <xref rid="psp412146-bib-0021" ref-type="ref">21</xref>, <xref rid="psp412146-bib-0022" ref-type="ref">22</xref>, <xref rid="psp412146-bib-0023" ref-type="ref">23</xref> The philosophy underlying all these AI methods is model prediction. Because they are distribution and assumption‐free, they test many important but collinear variables in simultaneous models, as are, for example, measures of weight, they also test nonlinear and high‐order interactions, not possible with standard PK approaches and software.<xref rid="psp412146-bib-0024" ref-type="ref">24</xref> Importantly, they do not assume what the structure of the covariate should be like.</p>
            <p>MARS, which was first introduced by Jerome Friedman<xref rid="psp412146-bib-0019" ref-type="ref">19</xref> in 1991, is an AI algorithm that combines adaptive recursive partitioning and spline‐fitting procedures in a manner that retains the positive aspects of both procedures in one algorithm. This makes MARS suitable for simultaneous analysis of linear, nonlinear, and highly dimensional inputs. Here, we used MARS, together with experimental study design, to examine nonlinear relationships between weight and clearance and volume of TMP‐SMX in obese subjects.</p>
            <sec id="psp412146-sec-0002">
              <title>METHODS</title>
              <sec id="psp412146-sec-0003">
                <title>Study design and setting</title>
                <p>This study was approved by the Institutional Review Boards of the University of Texas Southwestern Medical Center (042010‐069) and Texas Tech University Health Sciences Center (A10‐3592). The study was registered at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link> on July 20, 2010 (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> identifier: NCT01167452). We recruited healthy people 18 years of age or older without ear infections, urinary tract infections, bronchitis, traveler's diarrhea, <italic>Pneumocystis carinii</italic> pneumonia, or any other bacterial infection to determine study eligibility.</p>
                <p>We designed a clinical experiment in which we recruited and admitted 36 healthy adults distributed equally into the following BMI categories: &lt;25 kg/m<sup>2</sup>, 25–40 kg/m<sup>2</sup>, and &gt;40 kg/m<sup>2</sup>. Twelve volunteers with BMI &lt;25 kg/m<sup>2</sup>, or 25–40 kg/m<sup>2</sup>, or &gt;40 kg/m<sup>2</sup> were recruited. Each BMI group had 50% women and 50% men. People who were interested in the study were consented at the University of Texas Southwestern Clinical and Translational Research Center. People who were pregnant, had abnormal liver function tests (transaminases &gt;10 times upper limit of normal, alkaline phosphatase &gt;5 times upper limit of normal, total bilirubin &gt;5 times upper limit of normal, or history of allergy to sulfones, sulfonamides, or trimethoprim were excluded from study participation. People with a history of colon resection, gastric bypass, lap band, or any other condition that inhibits gastric absorption were not allowed to participate in the study. People who provided a signed informed consent, and were deemed eligible after a screening visit, were scheduled for admission in the University of Texas Southwestern Clinical and Translational Research Center for an overnight stay. Each person received a single supervised oral dose of TMP‐SMX (1600 mg/320 mg) under supervision of both the study nurse and physician in the Pharmacology Unit. Blood was drawn via an intravenous catheter just prior to the dose, and then at 1, 2, 4, 8, 12, and 24 hours after the drug dose. The seven different time points over 24 hours were chosen based on optimal sampling theory.<xref rid="psp412146-bib-0025" ref-type="ref">25</xref>, <xref rid="psp412146-bib-0026" ref-type="ref">26</xref> The intravenous catheter was removed after the 24‐hour blood draw, and the person was discharged from the study.</p>
              </sec>
              <sec id="psp412146-sec-0004">
                <title>Drug assay</title>
                <p>A robust liquid chromatography tandem mass spectrometry method for the analysis of TMP‐SMX, sulfamethazine content in plasma was developed and validated. Each 100 µL plasma sample was spiked with 100 µL of internal standard and protein was precipitated from the mixture using a 500 µL mixture of acetonitrile:methanol (80:20). The supernatant was removed, evaporated to dryness, and reconstituted with 100 uL of methanol:deionized water (50:50). Constituents of a 10‐µL injection volume were separated using a gradient elution and Kinetex column (2.6 µ, pentafluorophenyl 150 × 2.1 mm), and eluted using a gradient mobile phase (0.1% formic acid in deionized water:0.1% formic acid in methanol) at 0.25 mL/min. The total sample run time was 23.5 minutes; 10.5 minutes for sample separation and 13 minutes for equilibration. The precursor to product ions were detected using electrospray ionization‐tandem mass spectrometry in the positive ion mode with multiple reaction monitoring (trimethoprim, 291.1→230.0 and sulfamethoxazole, 253.9→156.0). The calibration curve was linear (r = 0.9990) with a 1 ng/mL lower limit of quantification and 1,500 ng/mL upper limit of quantification. Total analytical variation was &lt;5% relative SD; intra‐day and inter‐day precision and accuracy were &lt;5% relative SD.</p>
              </sec>
              <sec id="psp412146-sec-0005">
                <title>PK modeling</title>
                <p>We comodeled all 252 concentrations of either TMP or SMX using the ADAPT 5 program of D'Argenio <italic>et al</italic>.,<xref rid="psp412146-bib-0027" ref-type="ref">27</xref> and explored a one, two, and three‐compartment model with first‐order input and elimination, by implementing the maximum‐likelihood solution via the expectation‐maximization algorithm.<xref rid="psp412146-bib-0026" ref-type="ref">26</xref>, <xref rid="psp412146-bib-0027" ref-type="ref">27</xref> The best number of compartments was chosen using Akaike Information Criteria, Bayesian Information Criteria, and rules of parsimony (Occam's razor).<xref rid="psp412146-bib-0028" ref-type="ref">28</xref>, <xref rid="psp412146-bib-0029" ref-type="ref">29</xref>
</p>
              </sec>
              <sec id="psp412146-sec-0006">
                <title>MARS analysis</title>
                <p>MARS builds piecewise general additive models that describe nonlinear relationships between the target response and dependent variables allowing for simultaneous interactions between the covariates to change the slope between the target response and each variable using basis functions (BFs) defined within the dataspace. By means of knots or hinges for continuous variables or selected groups for ordinal or categorical variables, the BF essentially uses internal heuristics based on the data to build models. BFs that minimize mean squared errors are retained in a backward step elimination process. Because the MARS heuristic procedures are rooted in information theory, the BF knots define thresholds, which have been found to be physiologically meaningful in some of our prior work. Separate models were explored for each of the following dependent variables: volume, absorption constant, and elimination constant. The covariates included in each model were the following: self‐identified race, ethnic group, comorbid conditions, age, gender, height, weight, IBW, TBW, lean body weight, BSA, BMI, alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen levels, calculated creatinine clearance, and serum creatinine concentration. Because the MARS algorithms are inherently resistant to collinearity, have the ability to rank variable importance, and can assign surrogates for missing data, we examined models that included the measured height and weight, as well as calculated values from these, such as BMI, BSA, and IBW, in addition to the height and weight variables. The reason was to determine the best predictor for PK parameters, including those commonly used measures of patient's weight and metabolic function: each measure would be chosen in its own merit agnostically if it was good predictor. We used both the V‐fold cross‐validation procedure and the MARS legacy mode approaches to test selected models. All other options and limits were left in the default setting.</p>
              </sec>
              <sec id="psp412146-sec-0007">
                <title>Fractal geometry analyses</title>
                <p>If measures of body size were selected as significant predictors by MARS, we log‐transformed the values and PK parameter estimate, after Benoit Mandelbrot's foundational work with fractals.<xref rid="psp412146-bib-0010" ref-type="ref">10</xref>, <xref rid="psp412146-bib-0011" ref-type="ref">11</xref>, <xref rid="psp412146-bib-0012" ref-type="ref">12</xref>, <xref rid="psp412146-bib-0013" ref-type="ref">13</xref>, <xref rid="psp412146-bib-0014" ref-type="ref">14</xref>, <xref rid="psp412146-bib-0015" ref-type="ref">15</xref>, <xref rid="psp412146-bib-0030" ref-type="ref">30</xref>, <xref rid="psp412146-bib-0031" ref-type="ref">31</xref> In this approach, the slope of the relationship between PK parameter and a measure of body size is examined as fractal dimension. These factors were then reincorporated as potential predictors, and then examined using standard regression models, as described above.</p>
              </sec>
              <sec id="psp412146-sec-0008">
                <title>Software</title>
                <p>For compartmental PK analyses, we used the ADAPT 5 program of D'Argenio <italic>et al</italic>.<xref rid="psp412146-bib-0027" ref-type="ref">27</xref> MARS was implemented in Salford Systems Data Mining and Predictive Analytics Software (Salford Systems, San Diego, CA). Graphing was performed by importing data into GraphPad Prism 6 (GraphPad Software, La Jolla, CA).</p>
              </sec>
            </sec>
            <sec id="psp412146-sec-0009">
              <title>RESULTS</title>
              <p>The clinical and demographic characteristics in the subjects we recruited are shown in <bold>Table</bold>
<xref rid="psp412146-tbl-0001" ref-type="table-wrap">1</xref>. The weight ranged from 45–232 kg, a fivefold difference between the minimum and maximum TBW, demonstrating the intended wide weight range accomplished by the study design. The weight was not normally distributed. Forty‐four percent were patients with components of metabolic syndrome, with higher rates of 23% in BMI 25–40 kg/m<sup>2</sup> and 100% in the BMI &gt;40 kg/m<sup>2</sup> group compared to those with BMI &lt;25 kg/m<sup>2</sup>, as would be expected. With regard to adverse events, one person fainted during the screening blood draw, which we judged not to be related to the study drug. Three people (8.3%) developed a mild headache postdose, which was deemed possibly related to the study drug. One of the people who had a headache also had elevated blood pressure, skin irritation under the transparent medical dressing over the intravenous line insertion site, as well as a mild rash around the neck and ears; these reactions were not considered to be related to the study drug.</p>
              <table-wrap id="psp412146-tbl-0001" xml:lang="en" orientation="portrait" position="float">
                <label>Table 1</label>
                <caption>
                  <p>Clinical and demographic characteristics of 36 patients enrolled in the study</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/>
                  <col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/>
                  <thead valign="bottom">
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</th>
                      <th align="center" valign="bottom" rowspan="1" colspan="1">Median, range; no. of patients (%)</th>
                    </tr>
                  </thead>
                  <tbody valign="top">
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Female gender</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">18 (50)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Race</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">White</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">26 (72)</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Non‐white</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">10 (28)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Ethnicity</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hispanic</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">6 (17)</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Non‐Hispanic</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">30 (87)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Age, years</td>
                      <td align="char" char="–" valign="top" rowspan="1" colspan="1">37 (18–77)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Weight, kg</td>
                      <td align="char" char="–" valign="top" rowspan="1" colspan="1">89.95 (45.80–232)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">IBW, kg</td>
                      <td align="char" char="–" valign="top" rowspan="1" colspan="1">84.26 (51.48–172.13)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Height, m</td>
                      <td align="char" char="–" valign="top" rowspan="1" colspan="1">1.69 (1.55–2.05)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
</td>
                      <td align="char" char="–" valign="top" rowspan="1" colspan="1">30.25 (16.2–59.1)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Serum creatinine, mg/dL</td>
                      <td align="char" char="–" valign="top" rowspan="1" colspan="1">0.78 (0.54–1.26)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Creatinine clearance, nL/min</td>
                      <td align="char" char="–" valign="top" rowspan="1" colspan="1">129.94 (75.18–359.34)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Blood urea nitrogen, mg/dL</td>
                      <td align="char" char="–" valign="top" rowspan="1" colspan="1">12.5 (7–23)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">AST, U/L</td>
                      <td align="char" char="–" valign="top" rowspan="1" colspan="1">20.5 (12–59)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">ALT, U/L</td>
                      <td align="char" char="–" valign="top" rowspan="1" colspan="1">19.5 (8–76)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="psp412146-note-0001">
                    <p>ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; IBW, ideal body weight.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p><bold>Table</bold><xref rid="psp412146-tbl-0002" ref-type="table-wrap">2</xref> shows criteria scores for choosing the best SMX compartment model: by all criteria, the SMX concentrations were best described by a one‐compartment model. Specifically, this was not a two or three‐compartment model with fat mass and fat‐free mass as different compartments. The population PK parameter estimates values were not normally distributed for elimination constant and volume (D'Agostino normality test <italic>P</italic> &lt; 0.001), but the <italic>P</italic> value was 0.570 for absorption constant. The median (range) and percentage of coefficient of variation for elimination rate constant were: 0.060 (0.015–0.180) hr<sup>−1</sup> and 54.13%; for volume 9.60 (3.60–41.0) L and 62.84%; and for absorption constant 1.10 (0.46–1.90) hr<sup>−1</sup> and 31.26%. The observed vs. model predicted concentrations are shown in <bold>Supplementary Figure S1</bold>.</p>
              <table-wrap id="psp412146-tbl-0002" xml:lang="en" orientation="portrait" position="float">
                <label>Table 2</label>
                <caption>
                  <p>Comparison of a one, two, and three PK compartment model for TMP and SMX</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/>
                  <col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/>
                  <col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/>
                  <col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/>
                  <thead valign="bottom">
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" valign="bottom" rowspan="1" colspan="1"/>
                      <th align="center" valign="bottom" rowspan="1" colspan="1">One‐compartment</th>
                      <th align="center" valign="bottom" rowspan="1" colspan="1">Two‐compartment</th>
                      <th align="center" valign="bottom" rowspan="1" colspan="1">Three‐compartment</th>
                    </tr>
                  </thead>
                  <tbody valign="top">
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">SMX</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Akaike Information Criterion</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <bold>2,680.91</bold>
                      </td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2,690.24</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2,695.75</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Bayesian Information Criterion</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <bold>2,709.15</bold>
                      </td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2,732.59</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2,745.16</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Negative 2 log likelihood</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <bold>2,664.91</bold>
                      </td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2,666.24</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2,667.75</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">TMP</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Akaike Information Criterion</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <bold>1,191.04</bold>
                      </td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1,200.62</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1,212.85</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Bayesian Information Criterion</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <bold>1,219.27</bold>
                      </td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1,242.98</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1,262.27</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Negative 2 log likelihood</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">
                        <bold>1,175.04</bold>
                      </td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1,176.62</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1,184.85</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="psp412146-note-0003">
                    <p>The figures in bold represent best score.</p>
                  </fn>
                  <fn id="psp412146-note-0002">
                    <p>PK, pharmacokinetic; SMX, sulfamethoxazole; TMP, trimethoprim.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>Next, the SMX one‐compartment model parameter estimates for each patient were then examined together with all the potential anthropometric, clinical, laboratory, and other physiological predictors <italic>in toto</italic>, using MARS. MARS identifies local relationships in small data regions in a piecewise fashion, which are delineated by hinges, with output as BFs. The only predictor for the SMX elimination rate constant, of all 17 possible covariates, was patient weight in kilograms, which was described by the BF:max (0, WT‐45.8). This means that for patients with weight &gt;45.8 kg (i.e., the hinge), the weight was the significant predictor of elimination rate constant, otherwise for weight &lt;45 kg the effect was “0” (zero). It should be noted that the hinge was at the lowest weight in the dataset, thus, we examined for robustness and interpretability, including changes in the error rates. We used both the V‐fold cross‐validation procedure, in which the algorithm splits the dataset randomly into smaller datasets to identify post‐test prediction, and identified a post‐test R<sup>2</sup> of 0.51. Next, we examined the log‐log transformation of elimination rate constant and weight for the region of data identified by the hinge of weight &gt;45.8 kg, and identified the relationships shown in <bold>Figure</bold>
<xref rid="psp412146-fig-0001" ref-type="fig">1</xref>
<bold>a</bold>. The slope of that log‐log transformation was −0.74 ± 0.19 (<italic>P</italic> = 0.0004), almost exactly three‐fourths. This fractal dimension is well known in the relationship between metabolic rates and weight of organisms.<xref rid="psp412146-bib-0032" ref-type="ref">32</xref>, <xref rid="psp412146-bib-0033" ref-type="ref">33</xref> In <bold>Figure</bold>
<xref rid="psp412146-fig-0001" ref-type="fig">1</xref>
<bold>a</bold>, the relationship between log‐transformed SMX elimination rate constant (and, hence, clearance) and weight explained 98% of the variance. Since the total SMX concentration of the 24‐hour dosing interval, defined by the 0–24 hour area under the concentration‐time curve (AUC<sub>0–24</sub>), is given by <italic>f</italic> *dose/clearance (where <italic>f</italic> is absorbed fraction), this means that if the AI (MARS) findings are correct, then, in clinical terms, the SMX AUC<sub>0–24</sub> will be lower in heavier patients compared with leaner patients. <bold>Figure</bold>
<xref rid="psp412146-fig-0001" ref-type="fig">1</xref>
<bold>b</bold> shows that this is indeed the case using the AUC<sub>0–24</sub> derived trapezoidal method directly on the concentrations measured (not PK model‐derived). Uniquely, in <bold>Figure</bold>
<xref rid="psp412146-fig-0001" ref-type="fig">1</xref>
<bold>b</bold>, the slope of the log‐transformed data was −0.72 ± 0.14 (<italic>P</italic> &lt; 0.0001), also close to three‐fourths. These results directly confirm the clinical relevance of weight on SMX concentrations achieved, the accuracy of MARS algorithm in predictor selection of weight for elimination rate constant, and the fractal relationships, based on standard regression statistics.</p>
              <fig fig-type="Figure" xml:lang="en" id="psp412146-fig-0001" orientation="portrait" position="float">
                <label>Figure 1</label>
                <caption>
                  <p>Log‐log relationship between weight and sulfamethoxazole pharmacokinetics (PKs). The natural logarithm (Ln) was used for the log‐transformation of values. Both weight in kilograms and body mass index (BMI), as well as sulfamethoxazole (SMX) PK parameters and concentrations, were log‐transformed following the method of Mandelbroit <italic>et al</italic>.<xref rid="psp412146-bib-0030" ref-type="ref">30</xref>, <xref rid="psp412146-bib-0031" ref-type="ref">31</xref> (<bold>a</bold>) Shows the relationship between elimination rate (and thus xenobiotic metabolism and excretion) and weight in patients &gt;45.8 kg, which was three‐fourths. (<bold>b</bold>) Shows the slope of the relationships between the area under the concentration‐time curve (AUC), as derived by trapezoidal rule and weight, for which the log‐log slope was also three‐fourths. (<bold>c</bold>) Shows the relationship between volume and BMI in patients with BMI &gt;16.2 kg/m<sup>2</sup>, that is above the multiple adaptive regression splines‐derived hinge. (<bold>d</bold>) Shows the relationship between BMI and peak SMX concentration, which showed a slope of three‐fourths on log‐log transformation, unlike the volume of distribution.</p>
                </caption>
                <graphic id="nlm-graphic-1" xlink:href="PSP4-5-674-g001"/>
              </fig>
              <p>Using similar steps, MARS identified three factors associated with SMX volume of distribution as BMI, serum creatinine, and alkaline phosphatase levels, which were described by BFs in <bold>Table</bold>
<xref rid="psp412146-tbl-0003" ref-type="table-wrap">3</xref>, leading to the relationship:
<disp-formula id="psp412146-disp-0001"><label>(1)</label><mml:math id="nlm-math-1"><mml:mrow><mml:mtext>Volume</mml:mtext><mml:mo> </mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi mathvariant="normal">L</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo> </mml:mo><mml:mo>=</mml:mo><mml:mo> </mml:mo><mml:mn>5</mml:mn><mml:mo>.</mml:mo><mml:mn>24701</mml:mn><mml:mo> </mml:mo><mml:mo>+</mml:mo><mml:mo> </mml:mo><mml:mn>0.331725</mml:mn><mml:mo>*</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mtext>BF</mml:mtext></mml:mrow><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mo> </mml:mo><mml:mn>2</mml:mn><mml:mo>.</mml:mo><mml:mn>64024</mml:mn><mml:mo>*</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mtext>BF</mml:mtext></mml:mrow><mml:mn>5</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula>
</p>
              <table-wrap id="psp412146-tbl-0003" xml:lang="en" orientation="portrait" position="float">
                <label>Table 3</label>
                <caption>
                  <p>BFs for factors chosen as affecting SMX volume</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/>
                  <col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/>
                  <col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/>
                  <col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/>
                  <col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/>
                  <thead valign="bottom">
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" valign="bottom" rowspan="1" colspan="1">BF</th>
                      <th align="center" valign="bottom" rowspan="1" colspan="1">BF definition</th>
                      <th align="center" valign="bottom" rowspan="1" colspan="1">Coefficients</th>
                      <th align="center" valign="bottom" rowspan="1" colspan="1">No. (%) of affected patients</th>
                      <th align="center" valign="bottom" rowspan="1" colspan="1">Explanation (description of BF)</th>
                    </tr>
                  </thead>
                  <tbody valign="top">
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">BF<sub>0</sub>
</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">5.24701</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">36 (100)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">BF<sub>1</sub>
</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Max (0, BMI‐16.2)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.331725</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">35 (97)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">For each increase in BMI above 16.2, the volume of distribution increased by 33%</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">BF<sub>3</sub>
</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Max (0, ALT‐8)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1">33 (92)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Interacts with BF<sub>5</sub>
</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">BF<sub>5</sub>
</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Max (0, 0.78‐SCR)*BF<sub>3</sub>
</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">2.64024</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">17 (47)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Volume of distribution increased &gt;2.6 fold increase when ALT &gt;8 U/L and serum creatinine levels &lt;0.78 mg/dL</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="psp412146-note-0004">
                    <p>ALT, alanine aminotransferase; BF, basis function; BMI, body mass index; SCR, serum creatinine; SMX, sulfamethoxazole.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>In <bold>Table</bold>
<xref rid="psp412146-tbl-0003" ref-type="table-wrap">3</xref>, baseline serum creatinine levels and ALT levels were equally and highest ranked at 100%, followed closely by BMI at 69%. The three variables explained 64% of the variance in SMX volume of distribution, which is somehow reassuring. BF<sub>5</sub> is an example of a high‐order interaction: ALT levels &gt;8 U/L (i.e., BF<sub>3</sub> with hinge at 8 U/L) affected the effect of serum creatinine on volume, but only in people with serum creatinine &lt;0.78 mg/dL (i.e, hinge at 0.78 mg/dL). On the other hand, for BF<sub>1</sub>, the relationship between volume and BMI &gt;16.2 kg/m<sup>2</sup> (and not the BMI &gt;25 mg/m<sup>2</sup> standardly used to define overweight) was linear, and is shown in <bold>Figure</bold>
<xref rid="psp412146-fig-0001" ref-type="fig">1</xref>
<bold>c</bold>. The slope was 1.18 ± 0.25 (<italic>P</italic> &lt; 0.0001), based on standard frequentist regression. This illustrates the versatility of MARS in simultaneous delineation of linear and nonlinear relationships, as well as higher order interactions at the same time; once hinges are identified, standard regression methods confirmed the relationship. Because the effect of volume of distribution is best seen on peak drug concentration (peak is proportional to dose/volume), we plotted log values of the observed highest concentration (not PK model‐derived) vs. log BMI, which revealed the results shown in <bold>Figure</bold>
<xref rid="psp412146-fig-0001" ref-type="fig">1</xref>
<bold>d</bold>. The slope was −0.74 ± 0.18 (<italic>P</italic> = 0.0002), statistically similar to three‐fourths. On the other hand, MARS identified no predictors for the SMX absorption constant.</p>
              <p>For trimethoprim concentrations, PKs were also found to be best described by a one‐compartment model (<bold>Table</bold>
<xref rid="psp412146-tbl-0002" ref-type="table-wrap">2</xref>). The population PK parameter estimates values were not normally distributed for the elimination constant (<italic>P</italic> &lt; 0.0001) and volume (<italic>P</italic> = 0.034), but were normally distributed for absorption constant (<italic>P</italic> = 0.481). The median and percentage of coefficient of variation for the elimination rate constant were: 0.03 (0.02–0.14) hr<sup>−1</sup> and 51.19%; for volume 52 (16–141) L and 62.84%; and for absorption constant 2.10 (0.63–3.70) hr<sup>−1</sup> and 30.53%. The observed vs. model‐predicted concentrations are shown in <bold>Supplementary Figure S2</bold>.</p>
              <p>MARS identified both BMI and weight as the significant predictors of the trimethoprim elimination rate constant, attesting to the ability of the algorithm to break co‐linearity (BMI is calculated from weight) and revealing a complex nonlinear interaction. Both weight and BMI predicted 41% of the variance in the elimination rate constant. The relationship between these parameters and trimethoprim elimination rate constant was defined by the equation:
<disp-formula id="psp412146-disp-0002"><label>(2)</label><mml:math id="nlm-math-2"><mml:mrow><mml:mtext>Elimination</mml:mtext><mml:mo> </mml:mo><mml:mtext>rate</mml:mtext><mml:mo> </mml:mo><mml:mtext>constant</mml:mtext><mml:mo>=</mml:mo><mml:mo> </mml:mo><mml:mn>0.0399</mml:mn><mml:mo> </mml:mo><mml:mo>+</mml:mo><mml:mo> </mml:mo><mml:mn>0.00036</mml:mn><mml:mo>*</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mtext>BF</mml:mtext></mml:mrow><mml:mn>4</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula>where BFs are as defined in <bold>Table</bold>
<xref rid="psp412146-tbl-0004" ref-type="table-wrap">4</xref>. As is shown in <bold>Figure</bold>
<xref rid="psp412146-fig-0002" ref-type="fig">2</xref>
<bold>a</bold>, which is a log‐log plot, the relationship between patient's weight and trimethoprim elimination rate constant had a slope of −0.61 ± 0.17; the R<sup>2</sup>‐value was 0.28. <bold>Figure</bold>
<xref rid="psp412146-fig-0002" ref-type="fig">2</xref>
<bold>b</bold> shows the relationship between BMI and the trimethoprim elimination rate constant had a slope −0.56 ± 0.20; and the R<sup>2</sup> was 0.18. We also confirmed the effect of weight on the trapezoidal rule‐derived AUC<sub>0–24</sub>, with the log‐log plot shown in <bold>Figure</bold>
<xref rid="psp412146-fig-0002" ref-type="fig">2</xref>
<bold>c</bold>, which had a slope of 0.63 ± 0.14 (<italic>P</italic> &lt; 0.0001), a fractal dimension virtually the same as for ADAPT‐derived elimination rate and weight.</p>
              <fig fig-type="Figure" xml:lang="en" id="psp412146-fig-0002" orientation="portrait" position="float">
                <label>Figure 2</label>
                <caption>
                  <p>Log‐log relationship between weight and trimethoprim metabolism. The natural logarithm (Ln) was used for the log‐transformation of values. (<bold>a</bold>) Unlike sulfamethoxazole, the relationship between trimethoprim metabolism and weight in kilograms, did not obey the three‐fourths power laws, instead with a dimension of 0.61. (<bold>b</bold>) Similarly, body mass index vs. model‐derived elimination rate constant had a log‐log slope of 0.56. (<bold>c</bold>) Trapezoidal rule derived 0–24 hour area under the concentration‐time curve (AUC<sub>0–24</sub>) vs. weight regression revealed a log‐log slope that was virtually the same as for weight and elimination rate in panel <bold>a</bold>.</p>
                </caption>
                <graphic id="nlm-graphic-3" xlink:href="PSP4-5-674-g002"/>
              </fig>
              <table-wrap id="psp412146-tbl-0004" xml:lang="en" orientation="portrait" position="float">
                <label>Table 4</label>
                <caption>
                  <p>BFs for TMP elimination rate constant and volume</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/>
                  <col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/>
                  <col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/>
                  <col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/>
                  <col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/>
                  <thead valign="bottom">
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" valign="bottom" rowspan="1" colspan="1">BF</th>
                      <th align="center" valign="bottom" rowspan="1" colspan="1">BF definition</th>
                      <th align="center" valign="bottom" rowspan="1" colspan="1">Coefficients</th>
                      <th align="center" valign="bottom" rowspan="1" colspan="1">No. (%) of affected patients</th>
                      <th align="center" valign="bottom" rowspan="1" colspan="1">Description of BF</th>
                    </tr>
                  </thead>
                  <tbody valign="top">
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Elimination rate constant</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">BF<sub>0</sub>
</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Constant/intercept</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.03999123</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">BF<sub>2</sub>
</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Max (0, 78.5‐weight)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1">20 (56)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Weight in kg</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">BF<sub>4</sub>
</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Max (0, BMI‐16.2)*BF<sub>2</sub>
</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">0.00026024</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1">Interacts with BF<sub>2</sub>
</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Volume</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">BF<sub>0</sub>
</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Constant/intercept</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">32.4053</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">BF<sub>1</sub>
</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Max (0, BSA‐1.46631)</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">29.1674</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">35 (97)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">BF<sub>4</sub>
</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Max (0, 0.74‐SCR)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1">14 (39)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Interacts with BF<sub>5</sub>
</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">BF<sub>5</sub>
</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Max (0, AST‐12)*BF<sub>4</sub>
</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">18.7887</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">14 (39)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="psp412146-note-0005">
                    <p>AST, aspartate aminotransferase; BF, basis function; BMI, body mass index; BSA, body surface area; SCR, serum creatinine; TMP, trimethoprim.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>The predictors of trimethoprim volume were BSA, serum creatinine, and AST levels. The relationship was described by the equation:
<disp-formula id="psp412146-disp-0003"><label>(3)</label><mml:math id="nlm-math-3"><mml:mrow><mml:mtext>volume</mml:mtext><mml:mo> </mml:mo><mml:mo>=</mml:mo><mml:mo> </mml:mo><mml:mn>32</mml:mn><mml:mo>.</mml:mo><mml:mn>4053</mml:mn><mml:mo> </mml:mo><mml:mo>+</mml:mo><mml:mo> </mml:mo><mml:mn>29</mml:mn><mml:mo>.</mml:mo><mml:mn>1674</mml:mn><mml:mo>*</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mtext>BF</mml:mtext></mml:mrow><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mo> </mml:mo><mml:mn>18</mml:mn><mml:mo>.</mml:mo><mml:mn>7887</mml:mn><mml:mo>*</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mtext>BF</mml:mtext></mml:mrow><mml:mn>5</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula>where the BFs are as defined in <bold>Table</bold>
<xref rid="psp412146-tbl-0004" ref-type="table-wrap">4</xref>. The most important predictors were AST levels and serum creatinine levels at baseline equally weighted at the apex (100%), and interacting with each other, followed by BSA at 77% variable importance. The model shown in Eq. <xref rid="psp412146-disp-0003" ref-type="disp-formula">(3)</xref> explained 54% of trimethoprim volume of distribution variance. The log‐log relationship between BSA and trimethoprim volume had a slope of 1.312 ± 0.357 (<italic>P</italic> &lt; 0.001), as shown in <bold>Figure</bold>
<xref rid="psp412146-fig-0003" ref-type="fig">3</xref>
<bold>a</bold>. The slope is equivalent to the fractal four‐thirds, the inverse of three‐fourths. The change in volume of distribution with BSA would best be reflected by changes in peak concentration, which is what was found when peak concentration was plotted against BSA in <bold>Figure</bold>
<xref rid="psp412146-fig-0003" ref-type="fig">3</xref>
<bold>b</bold> in the range delineated by BF hinges using standard regression analysis. <bold>Figure</bold>
<xref rid="psp412146-fig-0003" ref-type="fig">3</xref>
<bold>b</bold> is not a log‐log slope, but had a slope of −3.73 ± 1.21 (inverse of one‐fourth), with a <italic>P</italic> = 0.004.</p>
              <fig fig-type="Figure" xml:lang="en" id="psp412146-fig-0003" orientation="portrait" position="float">
                <label>Figure 3</label>
                <caption>
                  <p>The relationship between body surface area and trimethoprim volume. The natural logarithm (Ln) was used for the log‐transformation of values. (<bold>a</bold>) A surprise was that body surface area was a predictor of trimethoprim volume of distribution, with a log‐log slope of four‐thirds or the inverse of three‐fourths. It would have been expected that these two parameters would be related by 1/length or height. (<bold>b</bold>) Interestingly, the observed peak concentration (amount of drug/volume of distribution) revealed a relationship characterized by the inverse of one‐fourth. Although these dimensions are unusual, they still, nevertheless, are part of the one‐fourth power laws.</p>
                </caption>
                <graphic id="nlm-graphic-5" xlink:href="PSP4-5-674-g003"/>
              </fig>
            </sec>
            <sec id="psp412146-sec-0010">
              <title>DISCUSSION</title>
              <p>Here, we show that different measures of body size, especially weight and BMI, have a profound effect on the xenobiotic metabolism of TMP‐SMX, as well as volume of distribution based on fractal geometry‐based relationships manifest as the three‐fourths and one‐fourth power law. However, none one‐fourth fractal signatures were also identified, including 0.63 for the log‐log relationship between weight and both trimethoprim elimination rate constant and AUC<sub>0–24</sub> as well as 1.18 for SMX volume and BMI. We show that the effect of body size on these PK parameters directly affects the concentrations achieved: larger and heavier patients achieved lower peak and AUC<sub>0–24</sub> concentrations than their leaner counterparts did. This led to a 5.6‐fold range difference in SMX AUC and 6.9‐fold in peak concentrations, for example. PK/PDs science using preclinical models has revealed that in virtually all antibiotics drug concentrations have a profound influence on microbial effect and resistance suppression: antibiotics have a concentration‐effect relationship.<xref rid="psp412146-bib-0034" ref-type="ref">34</xref> Several groups have shown the same on microbial response and resistance suppression in patients on antibacterial compounds, antifungal compounds, and antiparasitic compounds.<xref rid="psp412146-bib-0022" ref-type="ref">22</xref>
<sup>;</sup>
<xref rid="psp412146-bib-0035" ref-type="ref">35</xref>, <xref rid="psp412146-bib-0036" ref-type="ref">36</xref>, <xref rid="psp412146-bib-0037" ref-type="ref">37</xref>, <xref rid="psp412146-bib-0038" ref-type="ref">38</xref> We expect to see the same effects in obese patients treated with TMP‐SMX, which is used everywhere across the globe. PK/PD‐based studies for each of the almost 60 pathogens that this drug is used for are urgently needed in order to identify the optimal exposures to kill each pathogen, and with those results and our PK models, optimal doses designed for treatment of this large patient base, given the global burden of obesity. With this approach, dosing can be individualized by type of infection and patient weight.</p>
              <p>Second, our study shows the effect of fractal geometry of different measures of human body sizes on both xenobiotic metabolism and volumes of distributions of drugs. We have previously observed a similar impact of weight in kilograms and BMI on clearance and volume of echinocandin antifungals, antituberculous agents, and biologics.<xref rid="psp412146-bib-0011" ref-type="ref">11</xref>, <xref rid="psp412146-bib-0012" ref-type="ref">12</xref>, <xref rid="psp412146-bib-0013" ref-type="ref">13</xref>, <xref rid="psp412146-bib-0014" ref-type="ref">14</xref>, <xref rid="psp412146-bib-0015" ref-type="ref">15</xref> The current study also sheds light on what aspects of body size matter: there have been decades of old clinical debates as to whether such parameters as IBW (i.e., weight associated with maximum life expectancy), TBW, or lean body weight (TBW minus weight of body fat), BMI, or BSA should be used to dose. In the case of TMP‐SMX, the agnostic method MARS did not find IBW or lean body weight as important predictors. Instead, patient weight (and not dry weight) and BMI affected the elimination of both TMP and SMX. Unexpectedly, BSA had an effect on trimethoprim volume and peak concentrations. A literature search revealed that BSA dosing correction has been used with the cephalosporin cefotiam in Sumo wrestlers in Japan, and indeed is commonly used for dosing of cancer chemotherapy agents.<xref rid="psp412146-bib-0039" ref-type="ref">39</xref>
</p>
              <p>Third, our study has implications on study design for use in PK/PD studies in people, as well as statistical methods used to analyze these results. We demonstrated the versatility of AI analyses in identifying covariates of primary PK parameters. This is important for two reasons. First, these findings were confirmed by standard frequentist statistics. Essentially, MARS identified relationships and hinges at which of these relationships changed or ended, after which standard linear regression methods confirmed the same, with good <italic>P</italic> values. The latter was possible because selection of hinges avoids the problem of averaging out measures of association and slopes across data regions in which relationships change direction. In other words, the question is not about if there are differences in medians or slopes across two samples of populations, but if there are predictive relationships above and below certain covariate thresholds, and if these interact among themselves as well as with the main clinical pharmacology parameter. Second, there were some findings on MARS that while still present when frequentist approaches were used, no longer reached statistical significance. This is because of sample sizes. MARS and other AI methods require much smaller patient sample sizes to identify important clinical correlates, based on our prior work.<xref rid="psp412146-bib-0021" ref-type="ref">21</xref> The cross‐validation features of these algorithms allow for automatic creation of learning and test sets from the same data, so that the main outcome is predictive accuracy. Third, our study design was in the form of a clinical experiment. We recruited equal groups of patients targeted and stratified by weight bands, so that all other aspects were equal (i.e., <italic>ceteris paribus</italic>), except the weight and weight‐related comorbid conditions. This eliminates noise and bias, allowing for a smaller group of patients to be exposed to the study drug. Fourth, we applied optimal design methods and optimal sampling theory to identify when we would get blood samples, and targeted the most information‐rich timepoints. Our approach that incorporates these four factors into design and analyses offers a paradigm to minimize the numbers of patients exposed to drugs in PK studies that will use AI algorithms that can identify predictors from small numbers of samples.</p>
              <p>In conclusion, different measures of body size, especially weight and BMI, have a profound effect on the xenobiotic metabolism of TMP‐SMX as well as volume of distribution, based on fractal geometry based relationships. PD targets for TMP‐SMX are needed to help guide the dosing regimens for obese patients. The use of MARS and other AI methods require much smaller patient sample sizes to identify important clinical correlates, which is important given the small numbers of patients enrolled in many PK studies.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data">
                <caption>
                  <p>Supporting Information</p>
                </caption>
                <media xlink:href="PSP4-5-674-s001.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data">
                <caption>
                  <p>Supporting Information</p>
                </caption>
                <media xlink:href="PSP4-5-674-s002.doc">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data">
                <caption>
                  <p>Supporting Information</p>
                </caption>
                <media xlink:href="PSP4-5-674-s003.doc">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data">
                <caption>
                  <p>Supporting Information</p>
                </caption>
                <media xlink:href="PSP4-5-674-s004.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data">
                <caption>
                  <p>Supporting Information</p>
                </caption>
                <media xlink:href="PSP4-5-674-s005.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="psp412146-sec-0015">
              <title>Acknowledgments</title>
              <p>Grant KL2RR024983 (“North and Central Texas Clinical and Translational Science Initiative”) to the University of Texas Southwestern Medical Center from the National Center for Research Resources/National Institutes of Health supported R.G.H. Recruitment, admission of volunteers for the study, and collection of blood samples was performed by UT Southwestern Medical Center's Clinical and Translational Research Center personnel within the Center, which is supported by the National Institutes of Health Clinical and Translational Science Awards grant UL1RR024982.</p>
            </ack>
            <ack id="psp412146-sec-0016">
              <title>Conflict of Interest</title>
              <p>T.G. is the founder of Jacaranda Biomed Inc. R.G.H. is on the Advisory Board for Genetech. J.G.P., C.M., R.D.L., and M.S. declared no conflict of interest.</p>
            </ack>
            <ack id="psp412146-sec-0017">
              <title>Author Contributions</title>
              <p>R.G.H., J.G.P., C.M., R.D.L., M.S., and T.G. wrote the article. R.G.H., R.D.L., and T.G. designed the research. R.G.H., M.S., and T.G. performed the research. R.G.H., J.G.P., C.M., R.D.L., and T.G. analyzed the data.</p>
            </ack>
            <ref-list content-type="cited-references">
              <ref id="psp412146-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="miscellaneous" id="psp412146-cit-0001"><collab collab-type="authors">World Health Organization</collab>
. WHO Model List of Essential Medicine. 19th list. &lt;<ext-link ext-link-type="uri" xlink:href="http://www.who.int/medicines/publications/essentialmedicines/en/">http://www.who.int/medicines/publications/essentialmedicines/en/</ext-link>&gt;. Accessed 4 June 2016.
</mixed-citation>
              </ref>
              <ref id="psp412146-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0002"><string-name><surname>Hughes</surname>, <given-names>W.T.</given-names></string-name>, 
<string-name><surname>Feldman</surname>, <given-names>S.</given-names></string-name>, 
<string-name><surname>Chaudhary</surname>, <given-names>S.C.</given-names></string-name>, 
<string-name><surname>Ossi</surname>, <given-names>M.J.</given-names></string-name>, 
<string-name><surname>Cox</surname>, <given-names>F.</given-names></string-name> &amp; 
<string-name><surname>Sanyal</surname>, <given-names>S.K.</given-names></string-name>
<article-title>Comparison of pentamidine isethionate and trimethoprim‐sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia</article-title>. <source>J. Pediatr.</source>
<volume>92</volume>, <fpage>285</fpage>–<lpage>291</lpage> (<year>1978</year>).
<pub-id pub-id-type="pmid">304478</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0003"><string-name><surname>Furio</surname>, <given-names>M.M.</given-names></string-name>, 
<string-name><surname>Weidle</surname>, <given-names>P.J.</given-names></string-name>, 
<string-name><surname>Wordell</surname>, <given-names>C.J.</given-names></string-name> &amp; 
<string-name><surname>Liu</surname>, <given-names>H.H.</given-names></string-name>
<article-title>Management of Pneumocystis carinii pneumonia in patients with AIDS and other conditions: experience in a Philadelphia university teaching hospital</article-title>. <source>Pharmacotherapy</source>
<volume>8</volume>, <fpage>221</fpage>–<lpage>234</lpage> (<year>1988</year>).
<pub-id pub-id-type="pmid">3264066</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0004"><string-name><surname>Chin</surname>, <given-names>T.W.</given-names></string-name>, 
<string-name><surname>Vandenbroucke</surname>, <given-names>A.</given-names></string-name> &amp; 
<string-name><surname>Fong</surname>, <given-names>I.W.</given-names></string-name>
<article-title>Pharmacokinetics of trimethoprim‐sulfamethoxazole in critically ill and non‐critically ill AIDS patients</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>39</volume>, <fpage>28</fpage>–<lpage>33</lpage> (<year>1995</year>).
<pub-id pub-id-type="pmid">7695325</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="book" id="psp412146-cit-0005"><string-name><surname>Huxley</surname>, <given-names>J.S.</given-names></string-name><source>Problems of Relative Growth</source> (<publisher-name>The Dial Press</publisher-name>, <publisher-loc>New York</publisher-loc>, <year>1932</year>).
</mixed-citation>
              </ref>
              <ref id="psp412146-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0006"><string-name><surname>Green</surname>, <given-names>B.</given-names></string-name> &amp; 
<string-name><surname>Duffull</surname>, <given-names>S.B.</given-names></string-name>
<article-title>What is the best size descriptor to use for pharmacokinetic studies in the obese?</article-title>
<source>Br. J. Clin. Pharmacol.</source>
<volume>58</volume>, <fpage>119</fpage>–<lpage>133</lpage> (<year>2004</year>).
<pub-id pub-id-type="pmid">15255794</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0007"><string-name><surname>Kontis</surname>, <given-names>V.</given-names></string-name><italic>et al</italic><article-title>Regional contributions of six preventable risk factors to achieving the 25 x 25 non‐communicable disease mortality reduction target: a modelling study</article-title>. <source>Lancet Glob. Health</source><volume>3</volume>, <fpage>e746</fpage>–<lpage>e757</lpage> (<year>2015</year>).
<pub-id pub-id-type="pmid">26497599</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0008"><string-name><surname>Ogden</surname>, <given-names>C.L.</given-names></string-name>, 
<string-name><surname>Carroll</surname>, <given-names>M.D.</given-names></string-name>, 
<string-name><surname>Kit</surname>, <given-names>B.K.</given-names></string-name> &amp; 
<string-name><surname>Flegal</surname>, <given-names>K.M.</given-names></string-name>
<article-title>Prevalence of childhood and adult obesity in the United States, 2011–2012</article-title>. <source>JAMA</source>
<volume>311</volume>, <fpage>806</fpage>–<lpage>814</lpage> (<year>2014</year>).
<pub-id pub-id-type="pmid">24570244</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0009"><string-name><surname>Swinburn</surname>, <given-names>B.A.</given-names></string-name><italic>et al</italic><article-title>The global obesity pandemic: shaped by global drivers and local environments</article-title>. <source>Lancet</source><volume>378</volume>, <fpage>804</fpage>–<lpage>814</lpage> (<year>2011</year>).
<pub-id pub-id-type="pmid">21872749</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0010"><string-name><surname>Hall</surname>, <given-names>R.G.</given-names><suffix>2nd</suffix></string-name>, 
<string-name><surname>Swancutt</surname>, <given-names>M.A.</given-names></string-name>, 
<string-name><surname>Meek</surname>, <given-names>C.</given-names></string-name>, 
<string-name><surname>Leff</surname>, <given-names>R.D.</given-names></string-name> &amp; 
<string-name><surname>Gumbo</surname>, <given-names>T.</given-names></string-name>
<article-title>Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>56</volume>, <fpage>1502</fpage>–<lpage>1507</lpage> (<year>2012</year>).
<pub-id pub-id-type="pmid">22155817</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0011"><string-name><surname>Hall</surname>, <given-names>R.G.</given-names></string-name>, 
<string-name><surname>Swancutt</surname>, <given-names>M.A.</given-names></string-name> &amp; 
<string-name><surname>Gumbo</surname>, <given-names>T.</given-names></string-name>
<article-title>Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>55</volume>, <fpage>5107</fpage>–<lpage>5112</lpage> (<year>2011</year>).
<pub-id pub-id-type="pmid">21876061</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0012"><string-name><surname>Pasipanodya</surname>, <given-names>J.G.</given-names></string-name>, 
<string-name><surname>Hall</surname>, <given-names>R.G.</given-names><suffix>2nd</suffix></string-name> &amp; 
<string-name><surname>Gumbo</surname>, <given-names>T.</given-names></string-name>
<article-title>In silico‐derived bedside formula for individualized micafungin dosing for obese patients in the age of deterministic chaos</article-title>. <source>Clin. Pharmacol. Ther.</source>
<volume>97</volume>, <fpage>292</fpage>–<lpage>297</lpage> (<year>2015</year>).
<pub-id pub-id-type="pmid">25670351</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0013"><string-name><surname>Hall</surname>, <given-names>R.G.</given-names><suffix>2nd</suffix></string-name>, 
<string-name><surname>Swancutt</surname>, <given-names>M.A.</given-names></string-name>, 
<string-name><surname>Meek</surname>, <given-names>C.</given-names></string-name>, 
<string-name><surname>Leff</surname>, <given-names>R.</given-names></string-name> &amp; 
<string-name><surname>Gumbo</surname>, <given-names>T.</given-names></string-name>
<article-title>Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two‐thirds or three‐fourths</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>57</volume>, <fpage>2259</fpage>–<lpage>2264</lpage> (<year>2013</year>).
<pub-id pub-id-type="pmid">23459494</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0014"><string-name><surname>Jain</surname>, <given-names>M.K.</given-names></string-name>, 
<string-name><surname>Pasipanodya</surname>, <given-names>J.G.</given-names></string-name>, 
<string-name><surname>Alder</surname>, <given-names>L.</given-names></string-name>, 
<string-name><surname>Lee</surname>, <given-names>W.M.</given-names></string-name> &amp; 
<string-name><surname>Gumbo</surname>, <given-names>T.</given-names></string-name>
<article-title>Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>57</volume>, <fpage>1115</fpage>–<lpage>1120</lpage> (<year>2013</year>).
<pub-id pub-id-type="pmid">23183434</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0015"><string-name><surname>Hope</surname>, <given-names>W.W.</given-names></string-name><italic>et al</italic><article-title>Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing</article-title>. <source>Antimicrob. Agents Chemother.</source><volume>51</volume>, <fpage>3714</fpage>–<lpage>3719</lpage> (<year>2007</year>).
<pub-id pub-id-type="pmid">17638696</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0016"><string-name><surname>Breiman</surname>, <given-names>L.</given-names></string-name><article-title>Random forests</article-title>. <source>Machine Learning</source><volume>45</volume>, <fpage>5</fpage>–<lpage>32</lpage> (<year>2001</year>).
</mixed-citation>
              </ref>
              <ref id="psp412146-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0017"><string-name><surname>Swaminathan</surname>, <given-names>S.</given-names></string-name><italic>et al</italic><article-title>Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests</article-title>. <source>Clin. Infect. Dis.</source><volume>63</volume><issue>(suppl. 3)</issue>, <fpage>S63</fpage>–<lpage>S74</lpage> (<year>2016</year>).
<pub-id pub-id-type="pmid">27742636</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="book" id="psp412146-cit-0018"><string-name><surname>Breiman</surname>, <given-names>L.</given-names></string-name>, 
<string-name><surname>Friedman</surname>, <given-names>J.</given-names></string-name>, 
<string-name><surname>Stone</surname>, <given-names>C.J.</given-names></string-name> &amp; 
<string-name><surname>Olshen</surname>, <given-names>R.A.</given-names></string-name>
<source>Classification and Regression Trees</source> (<publisher-name>Chapman and Hall, CRC</publisher-name>, <publisher-loc>Boca Raton, FL</publisher-loc>, <year>1984</year>).
</mixed-citation>
              </ref>
              <ref id="psp412146-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0019"><string-name><surname>Friedman</surname>, <given-names>J.H.</given-names></string-name><article-title>Multivariate adaptive regression splines</article-title>. <source>Ann. Statist.</source><volume>19</volume>, <fpage>1</fpage>–<lpage>67</lpage> (<year>1991</year>).
</mixed-citation>
              </ref>
              <ref id="psp412146-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0020"><string-name><surname>Modongo</surname>, <given-names>C.</given-names></string-name>, 
<string-name><surname>Pasipanodya</surname>, <given-names>J.G.</given-names></string-name>, 
<string-name><surname>Zetola</surname>, <given-names>N.M.</given-names></string-name>, 
<string-name><surname>Williams</surname>, <given-names>S.M.</given-names></string-name>, 
<string-name><surname>Sirugo</surname>, <given-names>G.</given-names></string-name> &amp; 
<string-name><surname>Gumbo</surname>, <given-names>T.</given-names></string-name>
<article-title>Amikacin concentrations predictive of ototoxicity in multidrug‐resistant tuberculosis patients</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>59</volume>, <fpage>6337</fpage>–<lpage>6343</lpage> (<year>2015</year>).
<pub-id pub-id-type="pmid">26248372</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0021"><string-name><surname>Chigutsa</surname>, <given-names>E.</given-names></string-name><italic>et al</italic><article-title>Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis</article-title>. <source>Antimicrob. Agents Chemother.</source><volume>59</volume>, <fpage>38</fpage>–<lpage>45</lpage> (<year>2015</year>).
<pub-id pub-id-type="pmid">25313213</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0022"><string-name><surname>Pasipanodya</surname>, <given-names>J.G.</given-names></string-name>, 
<string-name><surname>McIlleron</surname>, <given-names>H.</given-names></string-name>, 
<string-name><surname>Burger</surname>, <given-names>A.</given-names></string-name>, 
<string-name><surname>Wash</surname>, <given-names>P.A.</given-names></string-name>, 
<string-name><surname>Smith</surname>, <given-names>P.</given-names></string-name> &amp; 
<string-name><surname>Gumbo</surname>, <given-names>T.</given-names></string-name>
<article-title>Serum drug concentrations predictive of pulmonary tuberculosis outcomes</article-title>. <source>J. Infect. Dis.</source>
<volume>208</volume>, <fpage>1464</fpage>–<lpage>1473</lpage> (<year>2013</year>).
<pub-id pub-id-type="pmid">23901086</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0023"><string-name><surname>Gumbo</surname>, <given-names>T.</given-names></string-name>, 
<string-name><surname>Hiemenz</surname>, <given-names>J.</given-names></string-name>, 
<string-name><surname>Ma</surname>, <given-names>L.</given-names></string-name>, 
<string-name><surname>Keirns</surname>, <given-names>J.J.</given-names></string-name>, 
<string-name><surname>Buell</surname>, <given-names>D.N.</given-names></string-name> &amp; 
<string-name><surname>Drusano</surname>, <given-names>G.L.</given-names></string-name>
<article-title>Population pharmacokinetics of micafungin in adult patients</article-title>. <source>Diagn. Microbiol. Infect. Dis.</source>
<volume>60</volume>, <fpage>329</fpage>–<lpage>331</lpage> (<year>2008</year>).
<pub-id pub-id-type="pmid">18024052</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0024"><string-name><surname>Breiman</surname>, <given-names>L.</given-names></string-name><article-title>Statistical modeling: the two cultures</article-title>. <source>Statist. Sci.</source><volume>16</volume>, <fpage>199</fpage>–<lpage>231</lpage> (<year>2001</year>).
</mixed-citation>
              </ref>
              <ref id="psp412146-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0025"><string-name><surname>Reed</surname>, <given-names>M.D.</given-names></string-name><article-title>Optimal sampling theory: an overview of its application to pharmacokinetic studies in infants and children</article-title>. <source>Pediatrics</source><volume>104</volume>(<issue>3 Pt 2</issue>), <fpage>627</fpage>–<lpage>632</lpage> (<year>1999</year>).
<pub-id pub-id-type="pmid">10469805</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0026"><string-name><surname>Hiruy</surname>, <given-names>H.</given-names></string-name><italic>et al</italic><article-title>Subtherapeutic concentrations of first‐line anti‐TB drugs in South African children treated according to current guidelines: the PHATISA study</article-title>. <source>J. Antimicrob. Chemother.</source><volume>70</volume>, <fpage>1115</fpage>–<lpage>1123</lpage> (<year>2015</year>).
<pub-id pub-id-type="pmid">25505005</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="book" id="psp412146-cit-0027"><string-name><surname>D'Argenio</surname>, <given-names>D.Z.</given-names></string-name>, 
<string-name><surname>Schumitzky</surname>, <given-names>A.</given-names></string-name> &amp; 
<string-name><surname>Wang</surname>, <given-names>X.</given-names></string-name>
<source>ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software</source> (<publisher-name>Biomedical Simulations Resource</publisher-name>, <publisher-loc>Los Angeles, CA</publisher-loc>, <year>2009</year>).
</mixed-citation>
              </ref>
              <ref id="psp412146-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0028"><string-name><surname>Akaike</surname>, <given-names>H.</given-names></string-name><article-title>A new look at the statistical model identification</article-title>. <source>IEEE Trans. Automat. Contr.</source><volume>19</volume>, <fpage>716</fpage>–<lpage>723</lpage> (<year>1974</year>).
</mixed-citation>
              </ref>
              <ref id="psp412146-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0029"><string-name><surname>Ludden</surname>, <given-names>T.M.</given-names></string-name>, 
<string-name><surname>Beal</surname>, <given-names>S.L.</given-names></string-name> &amp; 
<string-name><surname>Sheiner</surname>, <given-names>L.B.</given-names></string-name>
<article-title>Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection</article-title>. <source>J. Pharmacokinet. Biopharm.</source>
<volume>22</volume>, <fpage>431</fpage>–<lpage>445</lpage> (<year>1994</year>).
<pub-id pub-id-type="pmid">7791040</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0030"><string-name><surname>Mandelbrot</surname>, <given-names>B.</given-names></string-name><article-title>How long is the coast of Britain? Statistical self‐similarity and fractional dimension</article-title>. <source>Science</source><volume>156</volume>, <fpage>636</fpage>–<lpage>638</lpage> (<year>1967</year>).
<pub-id pub-id-type="pmid">17837158</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="book" id="psp412146-cit-0031"><string-name><surname>Mandelbrot</surname>, <given-names>B.B.</given-names></string-name><source>The Fractal Geometry of Nature</source> (<publisher-name>W.H. Freeman and Company</publisher-name>, <publisher-loc>San Francisco, CA</publisher-loc>, <year>1982</year>).
</mixed-citation>
              </ref>
              <ref id="psp412146-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0032"><string-name><surname>West</surname>, <given-names>G.B.</given-names></string-name>, 
<string-name><surname>Brown</surname>, <given-names>J.H.</given-names></string-name> &amp; 
<string-name><surname>Enquist</surname>, <given-names>B.J.</given-names></string-name>
<article-title>A general model for the origin of allometric scaling laws in biology</article-title>. <source>Science</source>
<volume>276</volume>, <fpage>122</fpage>–<lpage>126</lpage> (<year>1997</year>).
<pub-id pub-id-type="pmid">9082983</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0033"><string-name><surname>West</surname>, <given-names>G.B.</given-names></string-name>, 
<string-name><surname>Savage</surname>, <given-names>V.M.</given-names></string-name>, 
<string-name><surname>Gillooly</surname>, <given-names>J.</given-names></string-name>, 
<string-name><surname>Enquist</surname>, <given-names>B.J.</given-names></string-name>, 
<string-name><surname>Woodruff</surname>, <given-names>W.H.</given-names></string-name> &amp; 
<string-name><surname>Brown</surname>, <given-names>J.H.</given-names></string-name>
<article-title>Physiology: why does metabolic rate scale with body size?</article-title>
<source>Nature</source>
<volume>421</volume>, <fpage>713</fpage>; discussion 714 (<year>2003</year>).
</mixed-citation>
              </ref>
              <ref id="psp412146-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0034"><string-name><surname>Ambrose</surname>, <given-names>P.G.</given-names></string-name><italic>et al</italic><article-title>Pharmacokinetics‐pharmacodynamics of antimicrobial therapy: it's not just for mice anymore</article-title>. <source>Clin. Infect. Dis.</source><volume>44</volume>, <fpage>79</fpage>–<lpage>86</lpage> (<year>2007</year>).
<pub-id pub-id-type="pmid">17143821</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0035"><string-name><surname>Srivastava</surname>, <given-names>S.</given-names></string-name>, 
<string-name><surname>Pasipanodya</surname>, <given-names>J.G.</given-names></string-name>, 
<string-name><surname>Meek</surname>, <given-names>C.</given-names></string-name>, 
<string-name><surname>Leff</surname>, <given-names>R.</given-names></string-name> &amp; 
<string-name><surname>Gumbo</surname>, <given-names>T.</given-names></string-name>
<article-title>Multidrug‐resistant tuberculosis not due to noncompliance but to between‐patient pharmacokinetic variability</article-title>. <source>J. Infect. Dis.</source>
<volume>204</volume>, <fpage>1951</fpage>–<lpage>1959</lpage> (<year>2011</year>).
<pub-id pub-id-type="pmid">22021624</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0036"><string-name><surname>Dorlo</surname>, <given-names>T.P.</given-names></string-name><italic>et al</italic><article-title>Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure</article-title>. <source>J. Infect. Dis.</source><volume>210</volume>, <fpage>146</fpage>–<lpage>153</lpage> (<year>2014</year>).
<pub-id pub-id-type="pmid">24443541</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0037"><string-name><surname>Forrest</surname>, <given-names>A.</given-names></string-name>, 
<string-name><surname>Nix</surname>, <given-names>D.E.</given-names></string-name>, 
<string-name><surname>Ballow</surname>, <given-names>C.H.</given-names></string-name>, 
<string-name><surname>Goss</surname>, <given-names>T.F.</given-names></string-name>, 
<string-name><surname>Birmingham</surname>, <given-names>M.C.</given-names></string-name> &amp; 
<string-name><surname>Schentag</surname>, <given-names>J.J.</given-names></string-name>
<article-title>Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>37</volume>, <fpage>1073</fpage>–<lpage>1081</lpage> (<year>1993</year>).
<pub-id pub-id-type="pmid">8517694</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0038"><string-name><surname>Gumbo</surname>, <given-names>T.</given-names></string-name>, 
<string-name><surname>Angulo‐Barturen</surname>, <given-names>I.</given-names></string-name> &amp; 
<string-name><surname>Ferrer‐Bazaga</surname>, <given-names>S.</given-names></string-name>
<article-title>Pharmacokinetic‐pharmacodynamic and dose‐response relationships of antituberculosis drugs: recommendations and standards for industry and academia</article-title>. <source>J. Infect. Dis.</source>
<volume>211</volume>
<issue>(suppl. 3)</issue>, <fpage>S96</fpage>–<lpage>S106</lpage> (<year>2015</year>).
<pub-id pub-id-type="pmid">26009618</pub-id></mixed-citation>
              </ref>
              <ref id="psp412146-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="psp412146-cit-0039"><string-name><surname>Chiba</surname>, <given-names>K.</given-names></string-name>, 
<string-name><surname>Tsuchiya</surname>, <given-names>M.</given-names></string-name>, 
<string-name><surname>Kato</surname>, <given-names>J.</given-names></string-name>, 
<string-name><surname>Ochi</surname>, <given-names>K.</given-names></string-name>, 
<string-name><surname>Kawa</surname>, <given-names>Z.</given-names></string-name> &amp; 
<string-name><surname>Ishizaki</surname>, <given-names>T.</given-names></string-name>
<article-title>Cefotiam disposition in markedly obese athlete patients, Japanese sumo wrestlers</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>33</volume>, <fpage>1188</fpage>–<lpage>1192</lpage> (<year>1989</year>).
<pub-id pub-id-type="pmid">2802548</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
